Intrathecal immune reset in multiple sclerosis: exploring a new concept

Area of Science:

• Neuroimmunology
• Clinical Neurology
• Therapeutic Development

Background:

• Progressive multiple sclerosis (MS) pathology is poorly understood, and current treatments cannot halt its progression.
• Late-stage MS disability is linked to cortical subpial lesions and associated tertiary lymphoid organs (TLOs).
• TLOs can initiate localized immune responses, similar to intrathecal immune reactions observed in MS patients from diagnosis.

Purpose of the Study:

• To examine the consequences of intrathecal immune responses in MS.
• To propose targeting TLOs as a novel therapeutic strategy for progressive MS.
• To explore the potential of intrathecal drug delivery to reset the immune system and halt axonal damage.

Main Methods:

• Review of existing literature on MS pathology, intrathecal immunity, and TLOs.
• Analysis of the correlation between cortical lesions, TLOs, and clinical disability.
• Discussion of the potential of targeting B-lymphocytes and plasma cells within the intrathecal compartment.

Main Results:

• Intrathecal immune responses are associated with worse clinical prognosis and potential direct brain toxicity.
• Intrathecal secretion can serve as a surrogate marker for ongoing immune activity post-treatment.
• Tertiary lymphoid organs (TLOs) are implicated in triggering cortical lesions in MS.

Conclusions:

• Targeting TLO components represents a promising new therapeutic avenue for progressive MS.
• Intrathecal drug administration can leverage the blood-brain barrier (BBB) to safely modulate the immune system.
• A combination of monoclonal antibodies delivered intrathecally may be required for effective treatment, potentially leading to a one-shot therapy.